Experimental Hematology
Volume 36, Issue 5 , Pages 523-532 , May 2008

Meeting report: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD, May 13–16, 2007

  • Linda Wolff

      Affiliations

    • National Cancer Institute, Bethesda, Md., USA
    • Corresponding Author InformationOffprint requests to: Linda Wolff, Ph.D., National Institutes of Health, Building 37, Room 4124, 37 Convent Drive, MSC 4263, Bethesda, MD 20892
    • ,
  • Steven J. Ackerman

      Affiliations

    • University of Illinois at Chicago, Chicago, Ill., USA
    • ,
  • Giuseppina Nucifora

      Affiliations

    • University of Illinois at Chicago, Chicago, Ill., USA

Received 31 October 2007 ,Revised 13 December 2007 ,Accepted 21 December 2007.

References 

  1. Buzzeo MP, Scott EW, Cogle CR. The hunt for cancer-initiating cells: a history stemming from leukemia. Leukemia. 2007;21:1619–1627
  2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737
  3. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005;82:389–396
  4. Laiosa CV, Stadtfeld M, Graf T. Determinants of lymphoid-myeloid lineage diversification. Annu Rev Immunol. 2006;24:705–738
  5. de Jong JL, Zon LI. Use of the zebrafish system to study primitive and definitive hematopoiesis. Annu Rev Genet. 2005;39:481–501
  6. Lyons SE, Lawson ND, Lei L, et al. A nonsense mutation in zebrafish gata1 causes the bloodless phenotype in vlad tepes. Proc Natl Acad Sci U S A. 2002;99:5454–5459
  7. Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia. Int J Hematol. 2005;81:368–377
  8. DeKoter RP, Kamath MB, Houston IB. Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models. Blood Cells Mol Dis. 2007;39:316–320
  9. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science. 2000;288:1439–1441
  10. Dahl R, Walsh JC, Lancki D, et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol. 2003;4:1029–1036
  11. Laslo P, Spooner CJ, Warmflash A, et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell. 2006;126:755–766
  12. Dahl R, Iyer SR, Owens KS, Cuylear DD, Simon MC. The transcriptional repressor GFI-1 antagonizes PU.1 activity through protein-protein interaction. J Biol Chem. 2007;282:6473–6483
  13. Du J, Stankiewicz MJ, Liu Y, et al. Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem. 2002;277:43481–43494
  14. Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol. 2007;35:394–406
  15. Resendes KK, Rosmarin AG. GA-binding protein and p300 are essential components of a retinoic acid-induced enhanceosome in myeloid cells. Mol Cell Biol. 2006;26:3060–3070
  16. Yang ZF, Mott S, Rosmarin AG. The Ets transcription factor GABP is required for cell-cycle progression. Nat Cell Biol. 2007;9:339–346
  17. Yeamans C, Wang D, Paz-Priel I, Torbett BE, Tenan DG, Friedman AD. C/EBP{alpha} binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment. Blood. 2007;110:3136–3142
  18. Elagib KE, Goldfarb AN. Regulation of RUNX1 transcriptional function by GATA-1. Crit Rev Eukaryot Gene Exp. 2007;17:271–280
  19. Heuze ML, Guibal FC, Banks CA, et al. ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex. J Biol Chem. 2005;280:5468–5474
  20. Leeanansaksiri W, Wang H, Gooya JM, et al. IL-3 induces inhibitor of DNA-binding protein-1 in hemopoietic progenitor cells and promotes myeloid cell development. J Immunol. 2005;174:7014–7021
  21. Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia. 2002;16:549–558
  22. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene. 2004;23:7164–7177
  23. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926–935
  24. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2006;94:179–183
  25. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257–268
  26. Keeshan K, He Y, Wouters BJ, et al. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell. 2006;10:401–411
  27. Grosveld GC. MN1, a novel player in human AML. Blood Cells Mol Dis. 2007;39:336–339
  28. Muntean AG, Ge Y, Taub JW, Crispino JD. Transcription factor GATA-1 and Down syndrome leukemogenesis. Leuk Lymphoma. 2006;47:986–997
  29. Mikhail FM, Sinha KK, Saunthararajah Y, Nucifora G. Normal and transforming functions of RUNX1: a perspective. J Cell Physiol. 2006;207:582–593

PII: S0301-472X(08)00008-8

doi: 10.1016/j.exphem.2007.12.018

Experimental Hematology
Volume 36, Issue 5 , Pages 523-532 , May 2008

Article Tools

* Image Usage & Resolution